$12.12
6.41% today
Nasdaq, Apr 03, 06:33 pm CET
ISIN
US8162121045
Symbol
RNAC
Sector
Industry

Cartesian Therapeutics Stock price

$12.95
-4.55 26.00% 1M
-5.04 28.02% 6M
-4.96 27.69% YTD
-2.95 18.57% 1Y
-7.60 36.98% 3Y
-15.55 54.56% 5Y
-197.05 93.83% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.46 3.68%
ISIN
US8162121045
Symbol
RNAC
Sector
Industry

Key metrics

Market capitalization $335.50m
Enterprise Value $130.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.73
P/S ratio (TTM) P/S ratio 7.00
P/B ratio (TTM) P/B ratio 411.50
Revenue growth (TTM) Revenue growth 38.82%
Revenue (TTM) Revenue $47.94m
EBIT (operating result TTM) EBIT $-52.71m
Free Cash Flow (TTM) Free Cash Flow $-48.41m
Cash position $219.20m
EPS (TTM) EPS $-52.64
P/E forward negative
P/S forward 106.75
EV/Sales forward 41.67
Short interest 12.34%
Show more

Is Cartesian Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Cartesian Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Cartesian Therapeutics forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Cartesian Therapeutics forecast:

Buy
75%
Hold
25%

Financial data from Cartesian Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
48 48
39% 39%
100%
- Direct Costs 0.94 0.94
54% 54%
2%
47 47
45% 45%
98%
- Selling and Administrative Expenses 43 43
107% 107%
89%
- Research and Development Expense 56 56
18% 18%
117%
-52 -52
8% 8%
-108%
- Depreciation and Amortization 0.94 0.94
54% 54%
2%
EBIT (Operating Income) EBIT -53 -53
10% 10%
-110%
Net Profit -287 -287
693% 693%
-598%

In millions USD.

Don't miss a Thing! We will send you all news about Cartesian Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cartesian Therapeutics Stock News

Neutral
GlobeNewsWire
one day ago
FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On April 1, 2025, the Company issued to these employees options to purchase an aggregate of 31,000 shares...
Neutral
GlobeNewsWire
2 days ago
FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 2:15 p.m. ET.
Neutral
24/7 Wall Street
4 days ago
Retirement can be daunting, but it doesn't need to be. Imagine having an expert in your corner to help you with your financial goals.
More Cartesian Therapeutics News

Company Profile

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Head office United States
CEO Carsten Brunn
Founded 2007
Website www.cartesiantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today